Collaborative Pediatric Critical Care Research Network - Clinical Site

儿科重症监护协作研究网络 - 临床网站

基本信息

  • 批准号:
    10248818
  • 负责人:
  • 金额:
    $ 8.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-08-13 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT - Duke University Our overarching objective in joining the newly organized and expanded Collaborative Pediatric Critical Care Research Network (CPCCRN) as a new site is to enhance the scientific breadth and reach of the network to maximize its public health impact and improve outcomes for critically ill children. Our site, consisting of Duke University (primary site) in Durham, North Carolina, and the Medical University of South Carolina (MUSC; ancillary site) in Charleston, South Carolina, provides comprehensive care to > 4000 critically ill children per year in both states. Our sites provide access to 89 combined pediatric intensive care bed, and together, we will ensure that all critically ill children in the Carolinas have access to cutting edge clinical trials and research studies performed by the CPCCRN. We are committed to improving outcomes of critically ill children through collaborative multicenter clinical research. Over the past 3 years, we have enrolled >400 critically ill children in 15 clinical studies conducted at Duke and coordinated by leading multicenter clinical research networks. Our site based research team is supported by a comprehensive departmental and school of medicine wide clinical research infrastructure that provides full service administrative, financial, regulatory, and scientific support. Our proposed research coordinator, Mrs Harward, has >5 years of experience conducting multicenter clinical trials in critically ill children. Our proposed principal investigator, Dr. Hornik, has dedicated his professional life to improving outcomes of critically ill children through the development of safe and effective drugs and interventions. Dr. Hornik is board certified in pediatric critical care medicine and cardiology, has advanced training in biostatistics and pharmaceutical sciences, and a track record of enrolling critically ill children in clinical trials and mentoring early-career investigators. As a faculty member in both the Department of Pediatrics and the Duke Clinical Research Institute (DCRI), the world’s largest academic research organization, Dr. Hornik built a research and leadership portfolio ideally suited to enhance the scientific breadth of the CPCCRN. Leveraging our experience coordinating large multicenter pediatric clinical research networks, including the NICHD funded Pediatric Trials Network, the FDA supported Global Pediatric Clinical Trials Network, and the NCATS Trial Innovations Network, and the resources accessible through the Division of Quantitative Sciences and the DCRI Pharmacometrics Center, we will provide deep scientific expertise and training and mentoring opportunities for CPCCRN investigators in the areas of clinical pharmacology, real- world evidence generation, and regulatory science. Through our clinical reach and scientific expertise, we will contribute significantly to the success of the CPCCRN, development of talented clinician scientists, and completion of our highly innovative clinical trial aimed at reducing the morbidity and mortality of MODS in critically ill infants and children.
项目摘要/摘要-杜克大学

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christoph Hornik其他文献

Christoph Hornik的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christoph Hornik', 18)}}的其他基金

Digoxin Pharmacodynamics in Infants with Heart Failure due to Single Ventricle Congenital Heart Disease
地高辛在单心室先天性心脏病心力衰竭婴儿中的药效学
  • 批准号:
    10600853
  • 财政年份:
    2022
  • 资助金额:
    $ 8.67万
  • 项目类别:
Digoxin Pharmacodynamics in Infants with Heart Failure due to Single Ventricle Congenital Heart Disease
地高辛在单心室先天性心脏病心力衰竭婴儿中的药效学
  • 批准号:
    10464211
  • 财政年份:
    2022
  • 资助金额:
    $ 8.67万
  • 项目类别:
Collaborative Pediatric Critical Care Research Network - Clinical Site
儿科重症监护协作研究网络 - 临床网站
  • 批准号:
    10468849
  • 财政年份:
    2021
  • 资助金额:
    $ 8.67万
  • 项目类别:
Collaborative Pediatric Critical Care Research Network - Clinical Site
儿科重症监护协作研究网络 - 临床网站
  • 批准号:
    10393859
  • 财政年份:
    2021
  • 资助金额:
    $ 8.67万
  • 项目类别:
Collaborative Pediatric Critical Care Research Network - Clinical Site
儿科重症监护协作研究网络 - 临床网站
  • 批准号:
    10670245
  • 财政年份:
    2021
  • 资助金额:
    $ 8.67万
  • 项目类别:
Collaborative Pediatric Critical Care Research Network - Clinical Site
儿科重症监护协作研究网络 - 临床网站
  • 批准号:
    10470945
  • 财政年份:
    2021
  • 资助金额:
    $ 8.67万
  • 项目类别:
Collaborative Pediatric Critical Care Research Network - Clinical Site
儿科重症监护协作研究网络 - 临床网站
  • 批准号:
    10670216
  • 财政年份:
    2021
  • 资助金额:
    $ 8.67万
  • 项目类别:
Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia
西地那非在患有严重支气管肺发育不良的早产儿中的安全性
  • 批准号:
    10274808
  • 财政年份:
    2019
  • 资助金额:
    $ 8.67万
  • 项目类别:
Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia
西地那非在患有严重支气管肺发育不良的早产儿中的安全性
  • 批准号:
    10017313
  • 财政年份:
    2019
  • 资助金额:
    $ 8.67万
  • 项目类别:
Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia
西地那非在患有严重支气管肺发育不良的早产儿中的安全性
  • 批准号:
    9795582
  • 财政年份:
    2019
  • 资助金额:
    $ 8.67万
  • 项目类别:

相似海外基金

Planning Study for the Development of Sigma 2 ligands as Analgesics
Sigma 2 配体镇痛药开发规划研究
  • 批准号:
    10641500
  • 财政年份:
    2023
  • 资助金额:
    $ 8.67万
  • 项目类别:
Designing and validating optimal nonaddictive analgesics using the CANDO paradigm
使用 CANDO 范式设计和验证最佳的非成瘾性镇痛药
  • 批准号:
    10485593
  • 财政年份:
    2023
  • 资助金额:
    $ 8.67万
  • 项目类别:
Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain
植物 hHv1 通道阻滞剂作为神经性疼痛镇痛药的鉴定
  • 批准号:
    10728526
  • 财政年份:
    2023
  • 资助金额:
    $ 8.67万
  • 项目类别:
Development of LPA5 Antagonists as Analgesics
LPA5 拮抗剂镇痛药的开发
  • 批准号:
    10638278
  • 财政年份:
    2023
  • 资助金额:
    $ 8.67万
  • 项目类别:
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain
设计多种配体作为非阿片类镇痛药,用于治疗慢性疼痛
  • 批准号:
    10621646
  • 财政年份:
    2023
  • 资助金额:
    $ 8.67万
  • 项目类别:
Elucidation of the mechanism of pain suppression by exercise and development of new analgesics
阐明运动镇痛机制及开发新型镇痛药
  • 批准号:
    22K19602
  • 财政年份:
    2022
  • 资助金额:
    $ 8.67万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
  • 批准号:
    10425794
  • 财政年份:
    2022
  • 资助金额:
    $ 8.67万
  • 项目类别:
Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics
大麻素 CB1 受体变构靶向开发非成瘾性小分子镇痛药
  • 批准号:
    10512672
  • 财政年份:
    2022
  • 资助金额:
    $ 8.67万
  • 项目类别:
A novel clinically-relevant mouse model of chronic overlapping pain conditions for screening analgesics
用于筛选镇痛药的新型临床相关慢性重叠疼痛小鼠模型
  • 批准号:
    10821681
  • 财政年份:
    2022
  • 资助金额:
    $ 8.67万
  • 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
  • 批准号:
    10721752
  • 财政年份:
    2022
  • 资助金额:
    $ 8.67万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了